Concomitant neuroleptic malignant syndrome and diabetes insipidus

JAAPA. 2022 Aug 1;35(8):31-33. doi: 10.1097/01.JAA.0000840488.74228.46.

Abstract

Each year, nearly one-fifth of adults in the United States are prescribed at least one psychotropic medication. An increased trend in psychiatric polypharmacy has heightened awareness of drug-drug interactions and the tracking of adverse drug reactions. This article describes a patient who developed concomitant neuroleptic malignant syndrome (NMS) and nephrogenic diabetes insipidus during cross-titration of his antipsychotics while on lithium. The patient's mild form of NMS in turn caused hypovolemia and acute kidney injury. This case study highlights the dangers of polypharmacy and how it can obscure the presentation of even classic adverse reactions.

MeSH terms

  • Adult
  • Antipsychotic Agents* / adverse effects
  • Diabetes Insipidus* / chemically induced
  • Diabetes Insipidus* / complications
  • Diabetes Insipidus* / drug therapy
  • Diabetes Mellitus* / drug therapy
  • Drug Interactions
  • Humans
  • Neuroleptic Malignant Syndrome* / diagnosis
  • Neuroleptic Malignant Syndrome* / drug therapy
  • Neuroleptic Malignant Syndrome* / etiology
  • Polypharmacy

Substances

  • Antipsychotic Agents